Person:
ERDOĞAN, EZGİ BAŞAK

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
EZGİ BAŞAK
Last Name
ERDOĞAN
Name
Email Address
Birth Date

Filters

2015 - 20183
Reset filters

Settings

Author: Aydin, MEHMET × Author: Erdogan, EZGİ BAŞAK ×

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy
    (2015-08-01) ERGÜL, Nurhan; Kadioglu, HÜSEYİN; Yildiz, Seyma; YUCEL, Serap Baskaya; Gucin, ZÜHAL; Erdogan, EZGİ BAŞAK; Aydin, MEHMET; MUSLUMANOGLU, Mahmut; KADIOĞLU, HÜSEYİN; YILDIZ, ŞEYMA; GÜCİN, ZÜHAL; ERDOĞAN, EZGİ BAŞAK; AYDIN, MEHMET
    Background: Non-invasive evaluation of the extent of axillary nodal involvement in early-stage breast cancer (ESBC) patients and accurate assessment of multifocality are both challenging. Few reports have explored whether 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) might be more useful than other diagnostic methods in these contexts.
  • Thumbnail Image
    PublicationOpen Access
    Synchronous Hepatocellular Carcinoma and Cholangiocellular Carcinoma on F-18-FDG PET/CT
    (2018-10-01) Erdogan, EZGİ BAŞAK; Turk, HACI MEHMET; Tekce, ERTUĞRUL; Aydin, MEHMET; ERDOĞAN, EZGİ BAŞAK; TÜRK, HACI MEHMET; AYDIN, MEHMET
    A 43-year-old male patient presented with a mass lesion on the right liver lobe, segment 5, in radiological imaging and elevated alpha-fetoprotein levels (323 ng/mL) compatible with hepatocellular carcinoma (HCC). Positron emission tomography/computed tomography (PET/CT) images showed background level 18F-FDG uptake in the mass lesion. In addition, a secondary focus of increased 18F-FDG uptake was detected on the left liver lobe, segment 2, approximately 1,5 cm in diameter. Histopathological examination revealed HCC in the larger mass lesion with a lower 18F-FDG uptake, and cholangiocellular carcinoma in the smaller mass lesion with a higher 18F-FDG uptake. To our knowledge, this is the first case report of two histopathologically different primary malignant liver tumors in two distinct segments of the liver detected by PET/CT.
  • Thumbnail Image
    PublicationOpen Access
    Radioembolization Treatment for Liver Cancer
    (2016-04-01) Erdogan, EZGİ BAŞAK; Ozdemir, HÜSEYİN; Aydin, MEHMET; ERDOĞAN, EZGİ BAŞAK; ÖZDEMİR, HÜSEYIN; AYDIN, MEHMET
    Although curative treatment is surgery (resection/transplantation) and for small lesions ablative strategies, in primary liver carcinomas such as hepatocellular carcinoma and cholangiocellular carcinoma, palliative treatment is used for most of these patients because of lack of surgical options. These treatments are regional treatments such as transarterial chemoembolization, radiofrequency ablation, or microwave ablation and systemic treatments such as tyrosine kinase inhibitors. Surgery and chemotherapy are the main treatment options for metastatic liver tumors, particularly in colorectal tumors, although local treatment options are used for these patients. In recent years, transarterial radioembolization with yttrium-90 microsphere has emerged as a local treatment option in primary and metastatic liver tumors. The aim of this treatment is to provide an effective radiation dose distribution for the tumor in the liver tissue and to give the lowest dose in order to not harm the intact liver tissue. Radioembolization has proven to be as effective as other available palliative treatments in primary and secondary liver tumors and is a treatment method that is well tolerated. It has a risk for serious life-threatening complications, although this rate is low. Toxicity can be kept at a minimum with adequate technical and rigorous application in experienced hands and in accordance with multidisciplinarity. It is hoped that the effectiveness of radioembolization is further increased in the future by technological developments, researches on dosimetry, its use along with radiosensitizing agents, and various treatment combinations.